FDA Rethinks Phenylephrine Cold Remedies Effectiveness

Regulators move to phase out oral phenylephrine, citing lack of effectiveness against nasal congestion.

Dec 27, 2024

∙ Paid

A professional medical illustration focusing on the FDA's decision to phase out oral phenylephrine in cold medications due to ineffectiveness. The image features a clean, modern design with symbolic representations of nasal congestion, such as a simplified nasal passage diagram and medication capsules. Visual elements include a comparison of oral phenylephrine pills versus nasal sprays, emphasizing the effectiveness of sprays. Icons representing scientific research, such as magnifying glasses and molecular structures, add clarity. The color palette is calming and professional, with shades of blue and white, creating an approachable and informative style.

Topline:

The FDA plans to phase out oral phenylephrine, a common ingredient in cold medicines, after concluding it is ineffective for nasal congestion relief.

Study Details:

Phenylephrine, found in popular over-the-counter medications like Sudafed PE and DayQuil, has been a go-to remedy for nasal congestion for years. However, concerns about its effectiven…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.